åêðáéäåõóçó γ.ν.α.

466 Νεότερες εξελίξεις στα οξέα ισχαιμικά σύνδρομα χωρίς ανάσπαση του ST διαστήματος
2008;371:1587–1594.
21. Mukherjee D, Eagle KA, Kline-Rogers E et al. Impact of
prior peripheral arterial disease and stroke on outcomes
of acute coronary syndromes and effect of evidencebased
therapies (from the Global Registry of Acute
Coronary Events), Am J Cardiol 2007;100:1–6.
22. Ray KK, Morrow DA, Sabatine MS et al. Long-term prognostic
value of neopterin: a novel marker of monocyte
activation in patients with acute coronary syndrome,
Circulation 2007;115:3071–3078.
23. Morrow DA, Sabatine MS, Brennan ML et al. Concurrent
evaluation of novel cardiac biomarkers in acute coronary
syndrome: myeloperoxidase and soluble CD40 ligand
and the risk of recurrent ischaemic events in TACTICS-
TIMI 18, Eur Heart J 2008;29:1096–1102.
24. Kraaijeveld AO, de Jager SC, de Jager WJ et al. CC
chemokine ligand-5 (CCL5/RANTES) and CC chemokine
ligand-18 (CCL18/PARC) are specific markers of
refractory unstable angina pectoris and are transiently
raised during severe ischemic symptoms, Circulation
2007;116:1931–1941.
25. Omland T, Ueland T, Jansson AM et al. Circulating
osteoprotegerin levels and long-term prognosis in patients
with acute coronary syndromes, J Am Coll Cardiol
2008;51:627–633.
26. Tello-Montoliu A, Marin F, Patel J et al. Plasma angiogenin
levels in acute coronary syndromes: implications for
prognosis, Eur Heart J 2007;28:3006–3011.
27. Boos CJ, Soor SK, Kang D et al. Relationship between
circulating endothelial cells and the predicted risk of
cardiovascular events in acute coronary syndromes,
Eur Heart J 2007;28:1092–1101.
28. Altwegg LA, Neidhart M, Hersberger M et al. Myeloidrelated
protein 8/14 complex is released by monocytes
and granulocytes at the site of coronary occlusion: a
novel, early, and sensitive marker of acute coronary
syndromes, Eur Heart J 2007;28:941–948.
29. Morrow DA, Wang Y, Croce K et al. Myeloid-related
protein 8/14 and the risk of cardiovascular death or
myocardial infarction after an acute coronary syndrome
in the Pravastatin or Atorvastatin Evaluation and Infection
Therapy: Thrombolysis In Myocardial Infarction (PROVE
IT-TIMI 22) trial, Am Heart J 2008;155: 49–55.
30. Dai DF, Thajeb P, Tu CF et al. Plasma concentration of
SCUBE1, a novel platelet protein, is elevated in patients
with acute coronary syndrome and ischemic stroke, J
Am Coll Cardiol 2008;51:2173–2180.
31. Iakoubova OA, Sabatine MS, Rowland CM et al. Polymorphism
in KIF6 gene and benefit from statins after
acute coronary syndromes: results from the PROVE IT-
TIMI 22 study, J Am Coll Cardiol 2008;51:449–455.
32. Lanfear DE, Jones PG, Marsh S et al. Connexin37 (GJA4)
genotype predicts survival after an acute coronary syndrome,
Am Heart J 2007;154:561–566.
33. Chen WQ, Zhang M, Ji XP et al. Usefulness of high-frequency
vascular ultrasound imaging and serum inflammatory
markers to predict plaque rupture in patients
with stable and unstable angina pectoris, Am J Cardiol
2007;100:1341–1346.
34. Zethelius B, Berglund L, Sundstrom J et al. Use of multiple
biomarkers to improve the prediction of death from
cardiovascular causes, N Engl J Med 2008;358:2107–
2116.
35. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole
on the antiplatelet action of clopidogrel associated
with aspirin: the randomized, double-blind OCLA
(Omeprazole CLopidogrel Aspirin) study, J Am Coll
Cardiol 2008;51:256–260.
36. Frere C, Cuisset T, Morange PE et al. Effect of cytochrome
p450 polymorphisms on platelet reactivity after treatment
with clopidogrel in acute coronary syndrome, Am
J Cardiol 2008;101:1088–1093.
37. Di Sciascio G. ARMYDA-RELOAD. Presented at: ACC08.
March 29, 2008; Chicago, IL.
38. Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel
loading doses according to vasodilator-stimulated
phosphoprotein phosphorylation index decrease rate
of major adverse cardiovascular events in patients
with clopidogrel resistance: a multicenter randomized
prospective study, J Am Coll Cardiol 2008;51:1404–
1411.
39. Buch AN, Singh S, Roy P et al. Measuring aspirin resistance,
clopidogrel responsiveness, and postprocedural
markers of myonecrosis in patients undergoing
percutaneous coronary intervention, Am J Cardiol
2007;99:1518–1522.
40. Ho PM, Peterson ED, Wang L et al. Incidence of death
and acute myocardial infarction associated with stopping
clopidogrel after acute coronary syndrome, JAMA
2008;299:532–539.
41. Wiviott SD, Trenk D, Frelinger AL et al. Prasugrel
compared with high loading- and maintenance-dose
clopidogrel in patients with planned percutaneous
coronary intervention: the Prasugrel in Comparison
to Clopidogrel for Inhibition of Platelet Activation and
Aggregation–Thrombolysis in Myocardial Infarction 44
trial, Circulation 2007;116:2923–2932.
42. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel
versus clopidogrel in patients with acute coronary
syndromes, N Engl J Med 2007;357:2001–2015.
43. Wiviott SD, Braunwald E, McCabe CH et al. Intensive
oral antiplatelet therapy for reduction of ischaemic
events including stent thrombosis in patients with
acute coronary syndromes treated with percutaneous
coronary intervention and stenting in the TRITON-TIMI
38 trial: a subanalysis of a randomised trial, Lancet
2008;371:1353–1363.
44. Antman EM, Wiviott SD, Murphy SA et al. Early and late
benefits of prasugrel in patients with acute coronary
syndromes undergoing percutaneous coronary interven-